Berg R, Shebl A, Kimber MC, Abraham M, Schreiber GB. Hemolytic events associated withintravenous immune globulin therapy: a qualitative analysis of 263 cases reported to four
manufacturers between 2003 and 2012. Transfusion. 2015 Jul;55 Suppl 2:S36-46.
Basilua JM, Pochart P. Cotrimoxazole Prophylaxis Is Not Associated with a Higher occurrence ofAtazanavir Treatment Failure: analysis of Worldwide Pharmacovigilance Data. Infect Disord Drug
Targets. 2019 Dec 19. doi: 10.2174/1871526520666191220112416. [Epub ahead of print] PMID:
31858913
Botsis T, Woo EJ, Ball R. The contribution of the vaccine adverse event text mining system to theclassification of possible GuillainBarré Syndrome reports. Appl Clin Inform. 2013 Feb 27;4(1):88-99.
Botsis T, Woo EJ, Ball R. Application of Information Retrieval Approaches to Case Classification inthe Vaccine Adverse Event Reporting System. Drug Saf. 2013 May 24.
Card T, Ungaro R, Bhayat F, Blake A, Hantsbarger G, Travis S. Vedolizumab use is not associatedwith increased malignancy incidence: GEMINI LTS study results and post-marketing data. Aliment
Pharmacol Ther. 2020 Jan;51(1):149-157. doi: 10.1111/apt.15538. Epub 2019 Nov 20. PMID: 31747086
Castillon G, Salvo F, Moride Y. The Social Impact of Suspected Adverse Drug Reactions: An analysisof the Canada Vigilance Spontaneous Reporting Database. Drug Saf. 2018 Aug 19. doi:
10.1007/s40264-018-0713-8.
Chang LC, Mahmood R, Qureshi S, Breder CD. Patterns of use and impact of standardised MedDRA
query analyses on the safety evaluation and review of new drug and biologics license applications.
PLoS One. 2017 Jun 1;12(6).
Chernoff M, Ford-Chatterton H, Crain MJ.

The Use of the Medical Dictionary for Regulatory

Activities in the Identification of Mitochondrial Dysfunction in HIV-Infected Children. Case Studies
Bus Ind Gov Stat. 2012 Oct;5(1):17-31.
Chrétien B, Dolladille C, Hamel-Sénécal L, Sassier M, Faillie JL, Miremont-Salamé G, LelongBoulouard V, Le Boisselier R, Fedrizzi S, Alexandre J, Humbert X8. Comparative study of
hypoglycaemia induced by opioids. Is it a class effect? Expert Opin Drug Saf. 2019 Jul 24:1-6. doi:
10.1080/14740338.2019.1646246
Cloitre A, Duval X, Tubiana S, Giraud P, Veyrac G, Nosbaum A, Gouraud A, Mahé J, Lesclous P.
Antibiotic prophylaxis for the prevention of infective endocarditis for dental procedures is notassociated with fatal adverse drug reactions in France. Med Oral Patol Oral Cir Bucal. 2019 Apr 23.
pii: 22818. doi: 10.4317/medoral.22818.
de Boissieu P, Gaboriau L, Morel A, Trenque T. Bisphosphonate-related osteonecrosis of the jaw: datafrom the French national pharmacovigilance database. Fundam Clin Pharmacol. 2016 Jun 17.
Dupuch M, Dupuch L, Hamon T, Grabar N. Exploitation of semantic methods to cluster
pharmacovigilance terms. J Biomed Semantics. 2014 Apr 16;5(1):18.
Dupuch M, Grabar N. Semantic distance-based creation of clusters of pharmacovigilance terms andtheir evaluation. J Biomed Inform. 2015 Feb 4. pii: S1532-0464(14)00237-8.
Durup D(1), Schaffalitzky de Muckadell P(1), Strom CC(1). Evaluation of the reported rates ofhypersensitivity reactions associated with iron dextran and ferric carboxymaltose based on global
data from VigiBase™ and IQVIA™ MIDAS® over a ten-year period from 2008 to 2017. Expert Rev
Hematol. 2020 Mar 4. doi: 10.1080/17474086.2020.1738215. [Epub ahead of print] DOI:
10.1080/17474086.2020.1738215
Ettinger AB, LoPresti A, Yang H, Williams B, Zhou S, Fain R, Laurenza A. Psychiatric and behavioral
adverse events in randomized clinical studies of the noncompetitive AMPA receptor antagonist
perampanel. Epilepsia. 2015 Jul 3.
Felicetti P, Trotta F, Bonetto C, Santuccio C, Pernus YB, Burgner D, Chandler R, Girolomoni G,Hadden RD, Kochar S, Kukucu M, Monaco G, Ozen S, Pahud B, Phuong L, Bachtiar NS, Teeba A, TopK, Varricchio F, Wise RP18, Zanoni G19, Živkovic S, Bonhoeffer J; Brighton Collaboration Vasculitis
Working Group. Spontaneous reports of vasculitis as an adverse event following immunization: A
descriptive analysis across three international databases. Vaccine. 2015 Sep 18. pii: S0264410X(15)01293-1.
Fizazi K, Chi KN, de Bono JS, Gomella LG, Miller K, Rathkopf DE6Ryan CJ, Scher HI, Shore ND,
De Porre P, Londhe A, McGowan T, Pelhivanov N, Charnas R, Todd MB, Montgomery B. Low
Incidence of Corticosteroid-associated Adverse Events on Long-term Exposure to Low-dose
Prednisone Given with Abiraterone Acetate to Patients with Metastatic Castration-resistant ProstateCancer. Eur Urol. 2016 Mar 7.
Gahr M, Zeiss R, Lang D, Connemann BJ, Hiemke C, Schönfeldt-Lecuona C. Drug-induced liver
injury associated with antidepressive psychopharmacotherapy: An explorative assessment based on
quantitative signal detection using different MedDRA terms. J Clin Pharmacol. 2015 Oct 16.

Géniaux H, Assaf D, Miremont-Salamé G, Raspaud B, Gouverneur A, Robinson P, Pariente A, Salvo
F. Performance of the Standardised MedDRA® Queries for Case Retrieval in the French Spontaneous
Reporting Database. Drug Saf. 2014 Jun 19.
Gopal S, Hough D, Karcher K, Nuamah I, Palumbo J, Berlin JA, Baseman A, Xu Y, Kent J. Risk ofcardiovascular morbidity with risperidone or paliperidone treatment: analysis of 64 randomized,double-blind trials. J Clin Psychopharmacol. 2013 Apr;33(2):157-61.
Ji HH, Tang XW, Dong Z, Song L, Jia YT. Adverse Event Profiles of Anti-CTLA-4 and Anti-PD-1
Monoclonal Antibodies Alone or in Combination: Analysis of Spontaneous Reports Submitted toFAERS. Clin Drug Investig. 2019 Jan 23. doi: 10.1007/s40261-018-0735-0.
Morley R, Cardenas A, Hawkins P, Suzuki Y, Paton V, Phan SC, Merchant M, Hsu J, Yu W, Xia Q,
Koralek D, Luhn P, Aldairy W. Safety of Onartuzumab in Patients with Solid Tumors: Experience toDate from the Onartuzumab Clinical Trial Program. PLoS One. 2015 Oct 7;10(10):e0139679.
Ohyama K, Inoue M. Association between Selective Beta-adrenergic Drugs and Blood Pressure
Elevation: Data Mining of the Japanese Adverse Drug Event Report (JADER) Database. YakugakuZasshi. 2016; 136(7):1065-71.
Naganuma M, Tahara K, Hasegawa S, Fukuda A, Sasaoka S, Hatahira H, Motooka Y, Nakao S, Mukai
R, Hirade K, Yoshimura T, Kato T, Takeuchi H, Nakamura M. Adverse event profiles of solvent-based
and nanoparticle albumin-bound paclitaxel formulations using the Food and Drug Administration
Adverse Event Reporting System.

SAGE Open Med. 2019 Mar 11;7:2050312119836011. doi:

10.1177/2050312119836011.
Newbould V, Le Meur S, Goedecke T, Kurz X. Medication Errors: A Characterisation of Spontaneously
Reported Cases in EudraVigilance. Drug Saf. 2017 Jul 11.
Perino J, Mottal N, Bohbot Y, Servant V, Berroneau A, Poustis P, Fenaux P, Laribi K, Charbonnier A,Bilion E, Calmettes C, Bégaud B, Pigneux A, Milpied N, Miremont-Salamé G, Théophile H, DimicoliSalazar S. Cardiac failure in patients treated with azacitidine, a pyrimidine analogue: case reports
and disproportionality analyses in Vigibase®. Br J Clin Pharmacol. 2020 Jan 7. doi: 10.1111/bcp.14211.
[Epub ahead of print]
PMID: 31912911
Pollock RF, Biggar P. Indirect methods of comparison of the safety of ferric derisomaltose, iron sucroseand ferric carboxymaltose in the treatment of iron deficiency anemia. Expert Rev Hematol.
2020;13(2):187–195. doi:10.1080/17474086.2020.1709437
Raschi E, Poluzzi E1, Koci A, Antonazzo IC, Marchesini G, De Ponti F. Dipeptidyl peptidase-4
inhibitors and heart failure: Analysis of spontaneous reports submitted to the FDA Adverse Event
Reporting System. Nutr Metab Cardiovasc Dis. 2016 Feb 19.
Sakai T, Ohtsu F, Sekiya Y, Mori C, Sakata H, Goto N. Methodology for Estimating the Risk of Adverse
Drug Reactions in Pregnant Women: Analysis of the Japanese Adverse Drug Event Report Database.
Yakugaku Zasshi. 2016;136(3):499-505.
Sessa M, Mascolo A, Callréus T, Capuano A, Rossi F, Andersen M. Direct-acting oral anticoagulants(DOACs) in pregnancy: new insight from VigiBase®. Sci Rep. 2019 May 10;9(1):7236. doi:
10.1038/s41598-019-43715-4.
Shimada K, Hasegawa S, Nakao S, Mukai R, Matsumoto K, Tanaka M, Uranishi H1,, Masuta M,
Nishida S, Shimizu S, Hayashi Y, Suzuki A, Nakamura M. Adverse event profiles of ifosfamideinduced encephalopathy analyzed using the Food and Drug Administration Adverse Event Reporting
System and the Japanese Adverse Drug Event Report databases. Cancer Chemother Pharmacol.
2019 Sep 9. doi: 10.1007/s00280-019-03949-5.
Taylor E, Vu D, Legare C, Keene D. Intravenous immune globulin-related hemolysis: comparing two
different methods for case assessment. Transfusion. 2015 Jul;55 Suppl 2:S23-7.
Tieu C, Breder CD. A Critical Evaluation of Safety Signal Analysis Using Algorithmic Standardised
MedDRA Queries. Drug Saf. 2018 Aug 16. doi: 10.1007/s40264-018-0706-7.
Tourillon C, Mahe J, Baron A, Lambert A, Yélehé-Okouma M, Veyrac G, Jolliet P. Immediate-Type
Hypersensitivity Cross-Reactions to Proton Pump Inhibitors: A Descriptive Study of Data from theFrench National Pharmacovigilance Database. Int Arch Allergy Immunol. 2018 Nov 28:1-8. doi:
10.1159/000493581.
van Hunsel F, van de Koppel S, van Puijenbroek E, Kant A. Vitamin B6 in Health Supplements andNeuropathy: Case Series Assessment of Spontaneously Reported Cases. Drug Saf. 2018 May 8.
Ye JH, Ho YF, On AW, Chen WW, Huang YM, Huang WI, Tang YW. Trends in reporting drugassociated liver injuries in Taiwan: a focus on amiodarone. Int J Clin Pharm. 2018 Jul 26. doi:
10.1007/s11096-018-0698-5.

Zhu Z, Gao P, Hu Y, Wang J, Wang H, Yang J, Huang L, Ji C, Ni Y, Fang L. PEGylated versus nonPEGylated drugs: A cross-sectional analysis of adverse events in the FDA Adverse Event Reporting
System (FAERS) Database . Int J Clin Pharmacol Ther. 2020 Apr 23. doi: 10.5414/CP203735. [Epubahead of print] PubMed PMID: 32324132.